TACE is the standard of care for intermediate HCC that converts tumors into immune tumors by increasing tumor‐infiltrating lymphocytes and decreasing regulatory T cells and PD‐L1‐positive T cells due to inflammation of the tumor microenvironment after TAE/TACE [17, 18]. This evidence concerns the gene CD274 and hepatocellular carcinoma.